Related Experiment Video

Updated: May 15, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy

Yu Kyeong Han1, Jae Ho Lee, Ga-Young Park

  • 1Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan 619-953, Republic of Korea.

Biochemical and Biophysical Research Communications
|December 25, 2012
PubMed

Insights

A CDK4 inhibitor reduced cancer stem cell activity in MDA-MB-231 breast cancer cells, sensitizing them to radiation. This suggests potential for targeted therapy to improve radiotherapy efficacy.

Area of Science:

  • Oncology
  • Cancer Biology
  • Cellular Differentiation

Background:

  • Cancer stem cells (CSCs) drive tumor recurrence and therapy resistance.
  • Targeting CSCs is crucial for overcoming treatment failure.
  • Differentiation therapy offers a promising strategy to eliminate CSCs.

Purpose of the Study:

  • To investigate the effect of a CDK4 inhibitor on breast cancer cells, specifically focusing on cancer stem cell populations.
  • To determine if CDK4 inhibition can sensitize cancer cells to radiotherapy.
  • To explore the potential of CDK4 inhibitors as CSC-targeted therapies.

Main Methods:

  • Treatment of MDA-MB-231 and MCF7 breast cancer cell lines with a CDK4 inhibitor and irradiation.
  • Assessment of cell sensitization to irradiation.
  • Analysis of cancer stem cell markers and phenotypes following CDK4 inhibition.

Main Results:

  • The CDK4 inhibitor sensitized MDA-MB-231 cells, but not MCF7 cells, to irradiation.
  • CDK4 inhibition induced differentiation and reduced CSC activity in MDA-MB-231 cells.
  • The observed radiosensitization correlated with a reduction in the CSC population.

Conclusions:

  • CDK4 inhibitors may reduce CSC populations, leading to radiosensitization in certain breast cancer subtypes.
  • Targeting CSCs with CDK4 inhibitors could enhance radiotherapy efficacy.
  • Further research is warranted to explore CDK4 inhibitors for CSC-targeted breast cancer therapy.

More Related Videos

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...